Pharmaceuticals News and Research

RSS

M. D. Anderson wins $8.3-million to research environmental causes of major diseases

An $8.3-million federal grant to The University of Texas M. D. Anderson Cancer Center Science Park - Research Division addresses the complex interplay between such varied factors as genetics, diet, and environmental exposure to toxins that cause cancer, asthma, diabetes, cardiovascular and other diseases.

21 Apr 2007

ZARS announces Swedish marketing approval for Rapydan

ZARS, Inc. has announced that the Medical Products Agency in Sweden has approved Rapydan 70 mg/70 mg medicated plaster, a topical local anesthetic patch.

20 Apr 2007

Schering-Plough announces ZETIA spproved in Japan

Schering-Plough Corporation has announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for ZETIA (ezetimibe), a novel cholesterol-lowering agent that inhibits the absorption of cholesterol in the intestine.

20 Apr 2007

Generics are increasing competition and lower prescription drug prices

According to a new study by researchers at the Massachusetts Institute of Technology's (MIT) School of Management and Analysis Group Inc., there is no evidence that the recent increase in prevalence of authorized generics has resulted in delays in generic entry into the marketplace.

20 Apr 2007

Indevus Pharmaceuticals submits supplemental NDA for VALSTAR

Indevus Pharmaceuticals has announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval to reintroduce VALSTAR in the United States.

20 Apr 2007

Should government negotiate drug prices?

The following is written by Dr. Gary A. Puckrein, PhD, President and Chief Executive Officer of National Minority Quality Forum, on the topic of drug prices and the emerging majority:

20 Apr 2007

Natural ingredient in human blood found to block HIV-1

A new study has pinpointed a natural ingredient of human blood that effectively blocks HIV-1, the virus predominantly responsible for human AIDS, from infecting immune cells and multiplying.

20 Apr 2007

Alpharma moves into China with Tongde Pharmaceutical acquisition

Alpharma Inc. has announced it has acquired the assets of Shenzhou Tongde Pharmaceutical Co. Ltd ("Tongde") in Shenzhou City, China.

20 Apr 2007

Access Pharmaceuticals and Somanta Pharmaceuticals sign merger agreement

Access Pharmaceuticals and Somanta Pharmaceuticals have announced that they have signed a definitive merger agreement by which Access will acquire Somanta.

20 Apr 2007

Researchers finds meth receptor that could lead to therapy

A recently discovered signaling system in the brain has just been shown to be turned on by methamphetamine, an Oregon Health & Science University study found.

19 Apr 2007

HHS releases plan for development and purchase of medical countermeasures

HHS Secretary Mike Leavitt has released for display in the Federal Register the Department's new roadmap for developing and purchasing medical countermeasures against a host of chemical, biological, radiological and nuclear (CBRN) threats.

19 Apr 2007

ADVENTRX announces positive data from multidrug therapy with cofactor

ADVENTRX Pharmaceuticals has announced positive results from preclinical studies using a multidrug treatment regimen including ANX-510 (CoFactor) at the American Association for Cancer Research (AACR) Annual Meeting.

19 Apr 2007

Purdue molecule could lead to first drug treatment for Alzheimer's disease

A molecule designed by a Purdue University researcher could lead to the first drug treatment for Alzheimer's disease.

18 Apr 2007

OncoGenex Technologies announces data from a Phase II clinical trial of OGX-011

The primary objective of this study was to assess the objective response rates (reduction in tumor size) when OGX-011 is combined with docetaxel in patients with metastatic or locally recurrent breast cancer.

18 Apr 2007

Indevus and Valera complete merger

Indevus Pharmaceuticals and Valera Pharmaceuticals have announced the completion of their previously announced merger, which became effective at 12:01 a.m., April 18, 2007.

18 Apr 2007

More effective therapies for individual cancers - personalized medicine

Genetic and epigenetic variations ensure that no two people are exactly alike, and the same holds true for any two cancers.

18 Apr 2007

Cell Genesys reports data from clinical trials of GVAX immunotherapy for prostate cancer

Evaluation of antibody responses in patients with advanced prostate cancer from these studies shows that the GVAX cell-based immunotherapy induces antibody responses to a broad array of prostate cancer- associated antigens, including some not previously known to be associated with prostate cancer.

18 Apr 2007

Avalon Pharmaceuticals announces results of AVN944 biomarker study

Avalon Pharmaceuticals has announced the results of an AVN944 biomarker study that utilized Avalon's proprietary AvalonRx technology to identify gene signatures that may be useful for patient stratification.

18 Apr 2007

Anadys Pharmaceuticals presents data showing ANA773 promotes anti-tumor activity of killer cells

Anadys Pharmaceuticals presented data from an in vitro study showing that the active metabolite of ANA773 promotes natural killer (NK) cell-mediated anti-tumor response by inducing cytokine secretion, cytolysis of tumor cells and enhanced antibody-dependent cellular cytotoxicity (ADCC), during a poster presentation at the Annual Meeting of the American Association of Cancer Research (AACR) in Los Angeles.

18 Apr 2007

Thrombogenics announces agreement with Millipore for commercialization of stem cell technology

ThromboGenics NV has announced that it has completed a global license agreement with Millipore Corporation under which ThromboGenics will exclusively license its technology for production of the proprietary stem cell culture medium marketed by Millipore as RESGRO(x).

17 Apr 2007